Statins, Fear Marketing, and the Problem With Anti-Medicine Influencers

We hear versions of the same story regularly. Someone has elevated cholesterol, an abnormal coronary calcium score, a strong family history, elevated lipoprotein(a), or another cardiovascular risk factor. Before the clinical discussion even begins, they have already been told online that statins are dangerous.

The source may be a podcast, an Instagram reel, a wellness newsletter, or someone using the title “Dr.” without being a clinician responsible for diagnosing cardiovascular disease or managing lipid-lowering therapy.

The message is often delivered with great certainty. Cholesterol has been misunderstood. Statins are toxic. Doctors prescribe them because they have been taught to treat numbers. An FDA warning is presented as proof that the medication should never have been prescribed.

That is where a legitimate discussion about medication risk can turn into fear marketing.

This Is Not About Being Pro-Statin or Anti-Statin

At HormoneSynergy®, we do not approach statins from an ideological position. We approach lipid management from cardiovascular risk.

Some patients do not need a statin. Some people can make substantial improvements through nutrition, exercise, weight reduction, better glucose regulation, blood pressure control, smoking cessation and other changes. Others develop side effects and need a lower dose, a different statin, less frequent dosing, or a non-statin medication.

There are also people with established cardiovascular disease, substantial coronary calcium, diabetes, severe hypercholesterolemia, elevated ApoB, high lipoprotein(a), chronic kidney disease, or a strong family history for whom leaving atherogenic lipoproteins untreated may carry considerably more risk than taking a medication.

The decision belongs in that context.

For more on the role of ApoB, see ApoB and Longevity: Cardiovascular Risk and Lipoprotein Particles. Our broader approach is explained in Preventive Cardiology and Silent Heart Disease Detection.

What Changed in the 2026 Cholesterol Guidelines?

The 2026 ACC/AHA multisociety guideline on dyslipidemia replaced the 2018 cholesterol guideline and reflects how much cardiovascular prevention has changed.

LDL cholesterol still matters, but the guideline no longer treats the standard lipid panel as the entire conversation. Primary prevention now uses the newer PREVENT-ASCVD risk equations, with additional information used to personalize risk when the calculator does not tell the whole story.

Lipoprotein(a) is now recommended at least once in adulthood. ApoB can be useful when standard cholesterol measurements may underestimate the burden of atherogenic particles, particularly in people with diabetes, elevated triglycerides, cardiovascular-kidney-metabolic disease, or very low treated LDL-C.

Coronary artery calcium can also help when the decision about lipid-lowering treatment remains uncertain. A calcium score does not replace clinical judgment, but evidence of coronary atherosclerosis changes the discussion considerably.

This is much closer to how preventive cardiology should work. The goal is not to find a cholesterol number and automatically prescribe a statin. It is to understand the person's exposure to atherogenic particles, determine whether atherosclerosis is already present, estimate future risk, and decide how aggressively that risk should be reduced.

What the FDA Cognitive Warning Actually Means

The FDA language about statins and cognition is frequently used online as evidence that statins cause dementia.

That is not what the warning says.

Current statin labeling acknowledges rare post-marketing reports of memory loss, forgetfulness, confusion and other cognitive symptoms. The reported symptoms have generally been nonserious and reversible after discontinuation.

Post-marketing reports are important because they can identify problems that deserve investigation. They do not, by themselves, establish that a medication causes a disease.

Randomized clinical trial evidence has not shown that statin therapy causes dementia or progressive cognitive decline. A 2025 systematic review and meta-analysis of randomized lipid-lowering trials involving more than 100,000 participants found no increase in dementia or cognitive impairment with lipid-lowering therapy.

Observational studies have gone further and frequently report lower rates of dementia among statin users. Those findings are interesting, but observational associations do not prove that statins prevent dementia. Differences in healthcare access, cardiovascular risk management, medication adherence and other factors can influence those results.

The most defensible conclusion is simpler: current evidence does not support the claim that statins cause dementia.

For a deeper discussion, see Statins and Alzheimer’s: What the Data Actually Shows.

Statin Side Effects Are Real. So Is the Nocebo Effect.

This is where both sides of the online argument can get into trouble.

People can experience statin-associated muscle symptoms. Drug interactions can increase statin exposure. Thyroid disease, strenuous exercise and other medical conditions can complicate the picture. Rare but serious muscle complications can occur.

A patient describing muscle pain or weakness after starting a statin should therefore not be told that the symptoms are imaginary.

At the same time, controlled trials have shown that expectation can contribute substantially to the symptoms people associate with statins.

The SAMSON trial followed patients who had previously stopped statins because of side effects. Participants received atorvastatin, placebo tablets and periods with no tablets without knowing which tablets they were taking. Average symptom scores were almost identical during statin and placebo periods. Approximately 90% of the additional symptom burden experienced while taking the statin was also experienced while taking placebo.

That does not mean 90% of all statin side effects are imaginary. It means symptoms attributed to medication can have more than one cause, and expectation is one of them.

The 2026 dyslipidemia guideline takes essentially the same position. It recognizes genuine statin-attributed symptoms while also noting that patient expectations can contribute to symptoms and medication discontinuation.

This is particularly important in an environment where someone may watch dozens of videos warning that a medication will cause muscle pain, weakness, brain fog or diabetes before swallowing the first tablet.

We discuss this further in Statins, Dementia & Side Effects: Separating Evidence From Influencer Myths.

What About Diabetes?

Statins can slightly increase blood glucose and can accelerate the progression from prediabetes to type 2 diabetes in some people who are already metabolically susceptible.

That deserves attention, especially in someone with insulin resistance, increasing visceral fat, rising A1c or other metabolic risk factors.

It does not mean the cardiovascular benefit disappears.

The 2026 guideline continues to advise against avoiding or discontinuing statin therapy solely because of this risk when the person's cardiovascular indication is strong. Instead, glucose regulation, nutrition, resistance training, body composition and the other metabolic drivers should be addressed alongside cardiovascular treatment.

That is a very different message from pretending the glucose effect does not exist. It puts the risk where it belongs: in context.

Credential Theater Makes Medical Misinformation Harder to Recognize

Patients also need to know what someone's credentials actually mean.

There are many legitimate doctoral degrees, and useful health information can come from researchers, pharmacists, dietitians, nurses, scientists and other professionals. The problem begins when credentials are presented in a way that leads the audience to assume clinical authority that the person does not have.

A doctorate in an unrelated field does not make someone qualified to diagnose coronary artery disease, interpret cardiovascular imaging, prescribe medication, manage statin intolerance, or determine whether an individual patient's cardiovascular risk justifies treatment.

When someone uses medical-sounding authority to discourage medication or screening, it is reasonable to ask what the person's clinical training actually is, whether they are licensed to provide the care being discussed, and whether they are responsible for what happens when a patient follows that advice.

We have written more broadly about this issue in Fake Doctors, AI Health Groups, and Wellness Marketing, Fake Doctors, AI Profiles, and Medical Misinformation Online, and When Online Doctors Misrepresent Experience.

The Same Rhetoric Shows Up Elsewhere

The concern is larger than statins.

A similar rhetorical pattern can be used around mammography, colonoscopy, vaccines, blood pressure medication, hormone therapy, diabetes treatment and other areas of preventive medicine. A legitimate limitation or adverse effect is identified, stripped of context, and then used to suggest that the entire intervention is dangerous or that conventional medicine has been hiding the truth.

Responsible medicine does not require pretending that screening tests or medications are perfect. Mammography can produce false positives. Colonoscopy carries procedural risks. Statins can cause side effects. Medications can be prescribed when lifestyle intervention deserved more attention.

Those are reasons for better medicine, not reasons to abandon medical judgment.

What Real Cardiovascular Risk Assessment Looks Like

A useful discussion about lipid treatment starts with the patient rather than the medication.

• What is the person's overall ASCVD risk?
• What are the LDL-C and non-HDL-C levels?
• Would ApoB add useful information?
• Has lipoprotein(a) been measured?
• Is diabetes, insulin resistance or chronic kidney disease present?
• Is there a family history of premature cardiovascular disease?
• Does the person smoke?
• What is the blood pressure?
• Is coronary calcium or other evidence of atherosclerosis already present?
• Has the patient already had a heart attack, stroke or other ASCVD event?
• What benefit is reasonably expected from additional lipid lowering?
• What side effects, concerns and treatment preferences does the patient have?

At HormoneSynergy®, cardiovascular risk is considered within a larger picture that may include vascular imaging, lipoproteins, glucose regulation, inflammation, visceral fat, body composition, sleep, hormones, nutrition, exercise and family history.

Not every person needs every test. The purpose of testing is to answer a clinical question, not to accumulate data.

Statins Do Not Replace Lifestyle

The idea that someone must choose between medication and lifestyle is another false argument.

Nutrition, physical activity, muscle mass, visceral fat, glucose regulation, blood pressure, sleep, smoking and alcohol intake all influence long-term cardiovascular health. Those foundations remain important whether someone takes a statin or not.

For some people, improving those factors may be enough to reach an acceptable risk level without medication. For others, genetics or established atherosclerosis mean that lifestyle alone will not lower atherogenic lipoproteins enough.

Using medication when it is needed does not make lifestyle less important. Improving lifestyle does not make medication unnecessary when significant residual risk remains.

If Someone Develops Statin Symptoms

Medication symptoms deserve investigation rather than an argument.

A thoughtful review may include the timing and character of the symptoms, the particular statin and dose, medication interactions, thyroid status, exercise and other possible causes of muscle symptoms. Depending on the circumstances, the clinician may consider a lower dose, a different statin, an alternate dosing schedule, a supervised rechallenge, or an evidence-based non-statin therapy.

The 2026 guideline includes ezetimibe, PCSK9 inhibitors and bempedoic acid among the available approaches when additional LDL lowering is needed or statin tolerance limits treatment.

The objective is not to force someone to tolerate a medication that makes them feel poorly. It is to find a tolerable strategy that addresses the cardiovascular risk that prompted treatment in the first place.

Medicine, Not Marketing

Our phrase Medicine, Not Marketing applies to both sides of this discussion.

We should not prescribe statins automatically because a cholesterol number crosses an arbitrary line. We should not dismiss a patient who reports side effects. We should not pretend lifestyle does not matter.

We also should not frighten people away from an effective treatment because distrust generates engagement online.

Cardiovascular disease develops over decades. ApoB-containing particles, genetics, blood pressure, metabolic health, smoking, kidney disease and other exposures contribute to that process. Once plaque is present, the conversation changes again.

The purpose of preventive cardiology is to understand that risk early enough to do something useful about it.

The question is not whether statins belong to the good side or the bad side of medicine. The question is what this person is at risk for, what the evidence shows, and what treatment gives that person the best chance of avoiding a preventable heart attack or stroke.

---

Frequently Asked Questions

Are statins dangerous?

Statins can cause side effects and are not appropriate for every person, but they have a long record of reducing cardiovascular events when used in appropriately selected patients. The decision should be based on individual cardiovascular risk, expected benefit, tolerance and patient preference.

Do statins cause dementia?

Current randomized clinical trial evidence does not show that statins cause dementia or progressive cognitive decline. FDA labeling does acknowledge rare post-marketing reports of generally nonserious and reversible cognitive symptoms. Observational studies sometimes associate statin use with lower dementia rates, but those studies do not prove that statins prevent dementia.

Can statins cause muscle pain?

Yes. Statin-associated muscle symptoms can occur. At the same time, controlled studies show that some symptoms attributed to statins also occur with placebo. Symptoms should be evaluated rather than automatically blamed on the medication or dismissed as a nocebo response.

Can statins increase blood sugar?

Statins can slightly increase blood glucose and may accelerate development of type 2 diabetes in some people who are already predisposed. Current cardiovascular guidelines do not recommend avoiding an otherwise indicated statin solely for this reason because the reduction in cardiovascular risk can outweigh the small diabetes risk in appropriately selected patients.

What does the 2026 cholesterol guideline say about ApoB and lipoprotein(a)?

The 2026 ACC/AHA dyslipidemia guideline recommends measuring lipoprotein(a) at least once in adulthood. ApoB testing can provide additional risk information in selected patients, particularly when triglycerides are elevated, diabetes or cardiometabolic disease is present, or standard cholesterol measurements may underestimate residual atherogenic particle burden.

Should I stop a statin because of something I saw online?

No medication should be started or stopped because of a social media post. If there is concern about side effects or whether treatment is necessary, the appropriate next step is to review cardiovascular risk, the indication for therapy, symptoms, medication interactions, laboratory findings and possible alternatives with a qualified clinician.

Longevity Medicine Education Series
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.

Return to the Longevity Medicine Guide →